IMTX is expected to report earnings to rise 47.59% to -25 cents per share on November 18
Q3'24
Est.
$-0.25
Q2'24
Beat
by $0.11
Q1'24
Beat
by $0.16
Q4'23
Beat
by $0.01
Q3'23
Beat
by $0.04
The last earnings report on August 13 showed earnings per share of -17 cents, beating the estimate of -28 cents. With 1.17M shares outstanding, the current market capitalization sits at 975.14M.
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer